Scarica l'app Stockscreener
22.57
0.22%
-0.05
Dopo l'orario di chiusura:
22.59
0.02
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BAX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$22.62
Aprire:
$22.6
Volume 24 ore:
8.51M
Relative Volume:
1.20
Capitalizzazione di mercato:
$11.66B
Reddito:
$11.32B
Utile/perdita netta:
$-981.00M
Rapporto P/E:
-11.56
EPS:
-1.9532
Flusso di cassa netto:
$714.00M
1 W Prestazione:
-0.04%
1M Prestazione:
+8.20%
6M Prestazione:
+14.86%
1 anno Prestazione:
-21.36%
Intervallo 1D:
$22.37
$22.92
Intervallo di 1 settimana:
$21.73
$23.52
Portata 52W:
$15.73
$29.35
Baxter International Inc Stock (BAX) Company Profile
Nome
Baxter International Inc
Settore
Industria
Telefono
(224) 948-2000
Indirizzo
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
22.57 | 11.68B | 11.32B | -981.00M | 714.00M | -1.9532 |
ISRG
Intuitive Surgical Inc
|
407.12 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
153.83 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.58 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
69.00 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
198.50 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Downgrade | Argus | Buy → Hold |
| 2025-08-04 | Downgrade | Stifel | Buy → Hold |
| 2025-08-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-26 | Ripresa | Goldman | Buy |
| 2025-02-24 | Aggiornamento | Argus | Hold → Buy |
| 2025-02-20 | Ripresa | Barclays | Overweight |
| 2024-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-06-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-18 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-18 | Reiterato | Raymond James | Outperform |
| 2022-02-18 | Reiterato | Stifel | Buy |
| 2022-02-18 | Reiterato | UBS | Neutral |
| 2022-02-18 | Reiterato | Wells Fargo | Overweight |
| 2022-02-11 | Iniziato | Goldman | Neutral |
| 2022-01-07 | Ripresa | Citigroup | Buy |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-09-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Downgrade | UBS | Buy → Neutral |
| 2020-12-15 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-09-04 | Downgrade | Argus | Buy → Hold |
| 2020-06-24 | Iniziato | Oppenheimer | Outperform |
| 2020-03-19 | Aggiornamento | Stifel | Hold → Buy |
| 2020-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-01-02 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Aggiornamento | Argus | Hold → Buy |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-05-17 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-06 | Reiterato | Citigroup | Neutral |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
Mostra tutto
Baxter International Inc Borsa (BAX) Ultime notizie
ETFs Investing in Baxter International Inc. Stocks - TradingView
Baxter stock reflects a diversified medical technology business - ad-hoc-news.de
Baxter International stock reflects a diversified medical portfolio and ongoing portfolio transforma - ad-hoc-news.de
Baxter International Inc. (BAX) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors - Business Wire
Retia Medical Adds Former Baxter Executive Christopher Benassi to Advisory Board - citybiz
Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh - TradingView
Citi Sticks to Its Sell Rating for Baxter International (BAX) - The Globe and Mail
Baxter Beats Stable Value Fund 401(k) Plan Suit, For Good - Law360
A Look at Baxter International Inc (BAX) After 3.9% Decline -- G - GuruFocus
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter International balances portfolio focus and steady operations - ad-hoc-news.de
Baxter International focuses on core medical technologies as investors watch US healthcare demand - ad-hoc-news.de
Baxter International Again Defeats 401(k) Stable Value Fund Suit - Bloomberg Law News
Baxter International (BAX) Is Up 7.2% After Dual Russell 2500 Index AdditionsWhat's Changed - simplywall.st
Baxter International's Q2 2026 Earnings: What to Expect - Yahoo Finance
The Sigma Spectrum Infusion SystemBaxter International targets smarter IV safety - ad-hoc-news.de
Baxter International focuses on core healthcare business as investors watch its portfolio moves - ad-hoc-news.de
Why Baxter International Inc (BAX) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Is Baxter International (BAX) Fully Valued On Its Russell 2500 Index Additions? - Yahoo Finance
Will Dual Russell 2500 Inclusion and Stronger Sentiment Change Baxter International's (BAX) Narrative? - Yahoo Finance
Baxter International balances medical technology breadth with long-term investment themes - ad-hoc-news.de
Why Is Baxter (NYSE:BAX) Featured Across Major US Indices? - Kalkine Media
Baxter International focuses on core portfolio as investors weigh long-term growth prospects - ad-hoc-news.de
Baxter International focuses on medical products as investors watch long-term strategy - ad-hoc-news.de
The Spectrum IQ Infusion System from Baxter Internationalsmart pumps push safer drug delivery - AD HOC NEWS
Baxter International focuses on medical products and patient care - AD HOC NEWS
The PrisMax SystemBaxter International extends care for chronic kidney patients - AD HOC NEWS
Baxter International Inc. Actuals & Estimates (SWB:BTL) - TradingView
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - Stock Traders Daily
Baxter International outlines its healthcare strategy as investors watch the stock - AD HOC NEWS
BAX News | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Baxter International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Baxter International stock on the company backdrop. Trading stays tied to the wider health care setu - AD HOC NEWS
Evercore ISI Group Lowers Price Target for Baxter International (BAX) to $22 | BAX Stock News - GuruFocus
Baxter International outlines its healthcare focus as investors watch the stock - AD HOC NEWS
The Exacta HD dialyzerBaxter International targets high-flux performance for US dialysis centers - AD HOC NEWS
Global Human Fibrinogen Concentrate Market Size/Share Worth USD 2.78 Billion by 2035 at a 11.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
A Look at Baxter International Inc (BAX) After 3.2% Decline -- G - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
BAX Investors Have Opportunity to Lead Baxter International, Inc - The National Law Review
Baxter International consensus picture on Wall Street, shares trade steadily on NYSE - AD HOC NEWS
Is Baxter International stock underperforming the S&P 500? - MSN
Lazard Equity Franchise Portfolio's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact - Bioscience Association Manitoba
Baxter International, Inc. (BAX) LawsuitInvestors Urged to Contact Levi & Korsinsky Before December 15, 2025 - The National Law Review
Sigma Spectrum Infusion System from Baxter International Inc.smart alerts in a compact pump - ad-hoc-news.de
Baxter International Inc.(NYSE: BAX) added to Russell 2500 Index - marketscreener.com
Lost Money on Baxter International, Inc. (BAX)? Contact Levi & Ko - The National Law Review
Levi & Korsinsky Notifies Baxter International, Inc. (BAX) Shareh - The National Law Review
Baxter International Inc Azioni (BAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):